GeneDx Launches 48-Hour Whole Genome Sequencing for Critical NICU and PICU Patients
GeneDx (Nasdaq: WGS), a leader in genomic health insights, has unveiled ultraRapid Whole Genome Sequencing, providing quick, comprehensive genomic results for neonatal and pediatric patients in the NICU and PICU in just 48 hours.
GeneDx has launched ultraRapid Whole Genome Sequencing, a cutting-edge genomic testing service designed to deliver faster, clinically actionable results for neonatal and pediatric patients in the NICU and PICU. This new test can provide results in just 48 hours, drastically reducing the time it takes to reach a diagnosis for critically ill infants and potentially shortening their stay in the NICU.
Genetic diseases are a leading cause of infant mortality, and diagnosing these conditions as early as possible is critical. Studies have shown that infants who do not receive a genetic diagnosis experience a NICU stay 15 to 20 days longer on average. ultraRapid genome sequencing addresses this by offering a quicker diagnosis, potentially reducing unnecessary medical interventions, accelerating the identification of the cause, and transforming the care process in a time-sensitive environment.
In addition to improving outcomes for patients, ultraRapid genome testing has significant cost-saving benefits. By providing an earlier diagnosis and allowing for more informed clinical decisions, it has the potential to generate over $15,000 in healthcare savings per child. Research suggests that a genetic diagnosis can influence the clinical management of more than 60% of critically ill infants, highlighting the immense value of incorporating genetic testing into standard care in the NICU and PICU.
Dr. Paul Kruszka, Chief Medical Officer at GeneDx, emphasized the importance of this advancement, stating, “Offering an ultraRapid genome is a testament to GeneDx’s commitment to shorten, and hopefully one day eliminate, the diagnostic odyssey for patients and their families.”
He continued, “Countless studies cite the benefits of an earlier diagnosis in children with genetic disease, and while we continue to invest in the ability to accelerate and improve access to testing, it is incumbent upon clinicians, health systems, policymakers, and payors to recognize the benefits of this testing and offer it to more patients.”
Currently, up to 25% of NICU patients are likely to have a genetic disorder, but fewer than 5% are tested for genetic conditions. GeneDx’s ultraRapid test aims to address this gap by making genetic testing more accessible to a larger number of patients. Starting in March, GeneDx’s ultraRapid test will be available through the GeneDx portal and via integration with Epic Aura, allowing healthcare systems to more easily offer this service to their patients.
GeneDx’s expertise in genomic testing has been built through its experience sequencing over 750,000 exomes and genomes. This wealth of experience, combined with innovative lab processes that improve efficiency and accuracy, positions GeneDx to offer genetic testing at scale. The company’s ability to optimize and automate various processes within its laboratory has helped reduce testing costs and increase the speed of diagnosis without compromising accuracy.
The ultraRapid Whole Genome Sequencing test is an addition to GeneDx’s broad range of genomic offerings, which includes exome, genome, and rapid genome tests. With this new tool, GeneDx continues to push the boundaries of what is possible in genetic testing, ensuring that patients, families, and healthcare providers have the information they need to make informed, timely decisions.
As GeneDx prepares to launch ultraRapid Whole Genome Sequencing, it continues to lead the way in improving health outcomes by making advanced genetic diagnostics accessible to all. Their commitment to personalized, targeted care is reinforced through the use of one of the world’s largest rare disease datasets, enabling them to provide comprehensive, clinically relevant insights that contribute to personalized health plans, accelerate drug discovery, and increase healthcare system efficiency.
In conclusion, ultraRapid genome sequencing by GeneDx offers a revolutionary solution for the NICU and PICU, delivering faster and more accurate genetic diagnoses that can directly impact patient outcomes. By reducing diagnostic delays, shortening hospital stays, and driving healthcare savings, this innovation holds the potential to significantly improve the care and quality of life for critically ill infants.
